Geonettle Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 9.00%
- Profit Growth 83.80%
- Ebitda 97.25%
- Net Worth -7.51%
- Total Assets 39.95%
About Geonettle Pharma
Geonettle Pharma Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 March 2017 (Seven years and ten months 16 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raj Singh and Nidhi Kumari serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2017PTC091820
-
Company No.
091820
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Mar 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Geonettle Pharma Private Limited offer?
Geonettle Pharma Private Limited offers a wide range of products and services, including Conveyor Systems & Components, Conveyor Components, Protein Powder, ON Protein Powder, Pharmaceutical Medicine, Lycopene Syrup, Dicyclomine Hydrochloride Medicine, Dicyclomine Paracetamol Tablets, Pain Relief Drugs & Pharmaceuticals, Diclofenac.
Who are the key members and board of directors at Geonettle Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Singh
|
Director | 30-Mar-2017 | Current |
|
Nidhi Kumari
|
Director | 30-Mar-2017 | Current |
Financial Performance of Geonettle Pharma.
Geonettle Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 9% increase. The company also saw a substantial improvement in profitability, with a 83.8% increase in profit. The company's net worth dipped by a decrease of 7.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geonettle Pharma?
In 2021, Geonettle Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Geonettle Pharma?
Unlock and access historical data on people associated with Geonettle Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geonettle Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geonettle Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.